Zacks Research Issues Pessimistic Forecast for ONCY Earnings

Key Points

• Zacks Research cut its FY2026 EPS forecast for Oncolytics Biotech to a loss of $0.27 per share from a projected loss of $0.24, matching the current consensus estimate.
• Oncolytics reported a quarterly loss of $0.08 per share, missing analysts’ expectations of a $0.05 loss. Despite mixed analyst views, the stock carries a “Moderate Buy” consensus rating with a $5.00 average price target.
• ONCY shares opened at $0.84, near the lower end of their 12-month range of $0.73 to $1.51, while institutional investors and hedge funds own 6.82% of the company.

Oncolytics Biotech Inc. (NASDAQ:ONCY - Free Report) - Equities researchers at Zacks Research reduced their FY2026 EPS estimates for shares of Oncolytics Biotech in a research report issued on Thursday, August 27th. Zacks Research analyst D. Bautz now expects that the company will post earnings of ($0.27) per share for the year, down from their previous forecast of ($0.24). The consensus estimate for Oncolytics Biotech's current full-year earnings is ($0.27) per share.

Oncolytics Biotech (NASDAQ:ONCY - Get Free Report) last announced its earnings results on Wednesday, August 12th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.03).

A number of other equities analysts also recently commented on the stock. HC Wainwright reduced their price objective on shares of Oncolytics Biotech to $5.00 and set a "buy" rating for the company in a research note on Wednesday, August 19th. Weiss Ratings raised Oncolytics Biotech from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Monday, July 13th. Finally, Wall Street Zen downgraded Oncolytics Biotech from a "hold" rating to a "sell" rating in a research report on Saturday, May 16th. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $5.00.

Oncolytics Biotech Stock Up 0.2%

Shares of ONCY stock opened at $0.84 on Wednesday. The firm has a market cap of $107.11 million, a PE ratio of -2.47 and a beta of 1.13. Oncolytics Biotech has a 12 month low of $0.73 and a 12 month high of $1.51. The company's fifty day simple moving average is $0.85 and its 200-day simple moving average is $0.91.

Institutional Trading of Oncolytics Biotech

A number of large investors have recently added to or reduced their stakes in ONCY. Renaissance Technologies LLC bought a new position in shares of Oncolytics Biotech in the 1st quarter valued at about $608,000. PFG Investments LLC raised its holdings in shares of Oncolytics Biotech by 131.0% in the 1st quarter. PFG Investments LLC now owns 52,900 shares of the company's stock valued at $45,000 after purchasing an additional 30,000 shares during the period. Susquehanna International Group LLP lifted its stake in Oncolytics Biotech by 224.6% in the 2nd quarter. Susquehanna International Group LLP now owns 134,129 shares of the company's stock valued at $127,000 after purchasing an additional 92,806 shares during the last quarter. CIBC Private Wealth Group LLC bought a new position in Oncolytics Biotech during the fourth quarter worth about $44,000. Finally, XTX Topco Ltd bought a new position in Oncolytics Biotech during the fourth quarter worth about $69,000. Institutional investors and hedge funds own 6.82% of the company's stock.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc NASDAQ: ONCY is a clinical-stage biotechnology company focused on the development of novel oncolytic viral therapies for the treatment of cancer. The company's lead investigational agent, pelareorep (Reolysin), is a proprietary formulation of reovirus engineered to selectively infect and destroy tumor cells while stimulating a systemic antitumor immune response. Oncolytics leverages the natural biology of the virus to enhance the activity of standard‐of‐care treatments and immune checkpoint inhibitors.

Pelareorep has progressed into multiple advanced clinical trials, with combination studies conducted in metastatic breast cancer, non‐small cell lung cancer and head and neck cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source